SequelSEC

NANOVIRICIDES, INC. NNVC

Pharmaceutical Preparations · CIK 0001379006 · Fiscal year ends 0630

Revenue
$0
Fiscal year ended 2026-06-30
Operating income
-$8.31M
Fiscal year ended 2026-06-30
Free cash flow
-$7.78M
Fiscal year ended 2026-06-30

Valuation, from the filing

Public float$21.53MMarket value of stock held by non-affiliates, as stated on the cover page for 2024-12-31
Float per share$1.24Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / equity2.9×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2024-12-31, not today, and each multiple below it uses the figures for the fiscal year ending 2025-06-30 — the year that filing covered.

How this compares in its industry

Percentile among the Pharmaceutical Preparations filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Current ratio2.66x19th

NANOVIRICIDES, INC. (NNVC) reported revenue of $0 and net income of -$8.22M for the fiscal year ended 2026-06-30. This page shows 4 annual periods of income statement, balance sheet and cash flow figures normalized from NANOVIRICIDES, INC.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

NANOVIRICIDES, INC. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302025-06-302024-06-302023-06-30
Revenue$0$0$0$0
Cost of revenueUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailable
Operating income-$8.31M-$9.59M-$8.52M-$8.94M
Net income-$8.22M-$9.47M-$8.29M-$8.59M
Research & development$4.71M$5.55M$5.44M$6.39M
Weighted-average diluted sharesshares 20.19Mshares 15.12Mshares 11.87Mshares 11.63M
Pretax income-$8.22MUnavailableUnavailableUnavailable
Income tax expenseUnavailableUnavailableUnavailableUnavailable
Diluted EPS$-0.41$-0.63$-0.70$-0.74
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailable
General & administrative$3.60M$4.04M$3.08M$2.55M
Selling & marketingUnavailableUnavailableUnavailableUnavailable

Balance

NANOVIRICIDES, INC. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302025-06-302024-06-302023-06-30
Cash & equivalents$2.79M$1.56M$4.80M$8.15M
Total assets$9.87M$8.82M$12.82M$16.90M
Current assets$3.16M$1.67M$4.97M$8.45M
Total liabilities$1.20M$1.30M$1.36M$2.03M
Current liabilities$1.19M$1.31M$1.36M$534.25K
Total equity incl. NCI$8.68M$7.52M$11.46M$14.87M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailable
Accounts payableUnavailableUnavailableUnavailableUnavailable

Cash flow

NANOVIRICIDES, INC. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302025-06-302024-06-302023-06-30
Operating cash flow-$7.70M-$8.48M-$6.32M-$5.67M
Capital expenditures$84.32K$56.96K$156.56K$151.71K
Investing cash flow-$84.32K-$56.96K-$156.56K-$151.71K
Financing cash flow$9.02M$5.30M$3.12M-$94.79K
Net change in cashUnavailableUnavailableUnavailableUnavailable
Stock-based compensationUnavailableUnavailableUnavailableUnavailable
Common dividends paidUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailable

Derived

NANOVIRICIDES, INC. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302025-06-302024-06-302023-06-30
Free cash flow-$7.78M-$8.54M-$6.47M-$5.82M
Gross marginUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailable
Current ratio2.66x1.28x3.66x15.81x
Revenue YoY growthUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open NNVC in the interactive workspace to inspect any figure back to its filing.

Source filings

10-K · Filed 2026-09-28View SEC filing
10-Q · Filed 2026-05-15View SEC filing
10-Q · Filed 2026-02-17View SEC filing
10-Q · Filed 2025-11-14View SEC filing
10-K · Filed 2025-09-29View SEC filing
10-Q · Filed 2025-05-15View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.